Find the PAD and neuropathy patients your practice is missing.
Up to 59% of patients with peripheral artery disease, and up to half of those with diabetic neuropathy, have no symptoms. When you refer out or do not test, they leave undiagnosed, and the missing documentation now costs your practice. Here is what changed in 2026, and what to look for in an in-office test.
Referring out, or not testing at all, is getting more expensive in 2026.
Up to 59% of patients with peripheral artery disease and up to half of those with diabetic neuropathy are asymptomatic. Without in-office testing, the window to intervene before amputation, stroke, or readmission closes silently, and the documentation gap has become a financial liability.
Documentation scrutiny
In a December 2025 OIG audit, 44% of sampled podiatry E/M claims did not comply with Medicare requirements, most often because documentation was insufficient or missing. Medicare's WISeR model, which began January 2026 in six states, adds AI-assisted prior authorization for selected services, including skin substitutes.
Wound-care reimbursement shift
CMS set a flat skin-substitute payment of $127.14/cm² effective January 1, 2026, replacing ASP-based rates that ran to $1,000/cm² or more for some products. Quantitative, audit-defensible ABI is no longer optional.
Value-based-care economics
ACOs and Medicare Advantage plans pay for prevented complications. A practice with no PAD or neuropathy testing is invisible in risk-adjustment data and forfeits chronic-disease revenue.
Sources: 2024 ACC/AHA/Multisociety Guideline for Lower Extremity PAD (asymptomatic PAD represents 20% to 59% of objectively proven PAD); Pop-Busui et al., Diabetic Neuropathy: A Position Statement by the American Diabetes Association, Diabetes Care 2017;40:136-154 (up to 50% of diabetic peripheral neuropathies may be asymptomatic); HHS OIG report A-09-22-03012, December 2025 (44 of 100 sampled claims did not comply; 27 insufficiently documented or undocumented); Congressional Research Service, WISeR Model overview, December 16, 2025; CY 2026 Medicare Physician Fee Schedule final rule (90 FR 49266, November 5, 2025), as corrected November 28, 2025 ($127.14 per cm²); HHS OIG report OEI-BL-24-00420, September 2025 (ASP-based payments of roughly $1,000 to $1,600 per cm² for some products). Accessed October 31, 2026.
Built for the practice, not just the patient.
Five reasons Smart-ABI is the defensible choice for early detection and durable practice revenue.
Only-in-class autonomic testing
Detect PAD and autonomic neuropathy in one seven-minute test. The sudomotor module is unique to the Smart-LEDA+ platform.
A real ABI, not a PPG substitute
True cuff-based, four-limb measurement with VPR waveforms and Doppler-correlated accuracy: the methodology CMS technical requirements are built around.
CPT-compliant by design
Built to qualify for CPT 93922, 93923, and 95923 from the first test, with reports formatted for audit defensibility.
We install, we train, we stay
Reps install the device on-site and train your medical assistants on the Smart-ABI Process, so an MA can run the test before the physician enters the room.
Documentation that protects revenue
Color-coded ABI/VPR reports with patient trending, signed by qualified specialists and EMR-ready: built to hold up to RAC audits and AI-driven claims review.
Ready to see it in your workflow?
Book a virtual or on-site demo and walk through the test with a Smart-ABI specialist.
Schedule a DemoEarly detection that pays for itself.
When the MA-driven Smart-ABI Process is followed, a single device can generate CPT-code revenue with little incremental staff time. One avoided amputation alone can repay the capital investment several times over.
- Designed to meet CMS technical requirements for CPT 93922, 93923, and 95923.
- Documentation formatted for audit defensibility and clawback protection.
- Benefits both fee-for-service and managed-care reimbursement.
A Smart-ABI specialist can walk through reimbursement for your practice.
Schedule a Demo →*Illustrative ROI modeling from Hyperion sales materials; actual reimbursement varies by payer, region, patient volume, and documentation. Not a guarantee of revenue.
See the test in your own workflow.
Book a demo and a Smart-ABI specialist will walk your team through patient selection, the MA-operated workflow, reimbursement, and the report your EMR receives.